DPYD Multiplex 50% AF gDNA, tap a thumbnail to see more views.
DPYD Multiplex 50% AF gDNA
The SensID DPYD Multiplex 50% AF gDNA Reference Material contains a selection of dihydropyrimidine dehydrogenase (DPYD) gene variants that influence the metabolism of 5-fluorouracil (5-FU), a drug commonly used in cancer treatment. In patients with impaired DPYD function, standard doses of 5-FU can lead to severe and potentially life-threatening toxicity. SensID’s DNA products are accurately quantified using standard techniques that are linked to internationally recognized reference materials. The DPYD Multiplex 50% AF gDNA Reference Material includes one vial with a mutant allele frequency of 50%. It utilizes well-characterized human genomic DNA from a proprietary cell line as the wild-type background. For further details, please refer to Tables 1 and 2.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- Ideal for NGS workflows
- Mutations included
- Additional mutations covered
- Ideal for validations and development
- Analyzing performance NGS pipeline
Reference Materials for Pharmacogenetics (PGx)
The DPYD Multiplex 50% AF gDNA universal control for testing dihydropyrimidine dehydrogenase (DPYD; DHP; DPD; DHPDHASE) that is not specific to any platform. The variants included were chosen based on published research and input from various working groups and thought leaders who advocate for the use of DPYD testing. Regulatory bodies such as the EMA and NHS recommend that all patients be screened for DPYD deficiency before starting systemic therapy with fluoropyrimidine drugs like 5-fluorouracil (5-FU), Capecitabine, Tegafur, and Flucytosine. This product contains one vial of genomic DNA at a 50% allele frequency for the specified mutations, supported by a thoroughly characterized genomic background. Mutations in this gene lead to DPYD deficiency, disrupting pyrimidine metabolism and causing thymine-uraciluria, which increases the risk of toxicity in cancer patients treated with 5-fluorouracil.
Therapeutic areas where DPYD mutation status is important:
– Colorectal cancer
– Gastric cancer, pancreatic cancer, esophageal cancer
– Breast cancer
– Squamous cell carcinoma of the head and neck
– Biliary tract cancers
– Non-small cell lung cancer (NSCLC)
– Systemic yeast and fungal infections caused by sensitive organisms
This product is particularly suited for Next Generation Sequencing (NGS) workflows, including:
– Validation and development of sequencing protocols (e.g., Whole Exome Sequencing (WES), Amplicon Sequencing) and PCR methods
– Calibration and optimization of instruments and workflows in DNA processing (e.g., DNA fragmentation through acoustic shearing, enzymatic digestion, or sonication)
– Evaluation of your NGS pipeline’s performance by comparing it to publicly available datasets.
- DPYD Multiplex 50% AF gDNA
Product is ready-to-use.
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Instruction for Use
Frequently paired with this kit
Other assays and instruments lab teams add alongside the DPYD Multiplex 50% AF gDNA.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
